Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Spirapril Hydrochloride

FDA-approved product (tablet, oral), marketed as Renormax.

Registered studies
3
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Spirapril Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Ace inhibitors, plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli31.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae19.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

3registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Spirapril Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Spirapril Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study

    NCT07262710 · start 2025-12-01

    Registered record
    Registry ID
    NCT07262710
    Conditions
    Post-stroke Pneumonia
    Interventions
    angiotensin converting enzyme inhibitors; Calcium Channel Blockers; Angiotensin Receptor Blockers
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-12-01
    Completion
    2026-08-19
    Enrolment
    13,656

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-stroke Pneumonia
    Interventionangiotensin converting enzyme inhibitors; Calcium Channel Blockers; Angiotensin Receptor Blockers
    PhaseNot recorded
    Registry statusNot yet recruiting

  • NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients

    NCT02817360 · start 2016-02

    Registered record
    Registry ID
    NCT02817360
    Conditions
    Heart Diseases; Diabetes Mellitus, Type 2
    Interventions
    RAS-antagonist and beta-blocker up-to maximal dosages; RAS-antagonist and beta-blocker none or at stable dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2016-02
    Completion
    2026-12
    Enrolment
    2,400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Diseases; Diabetes Mellitus, Type 2
    InterventionRAS-antagonist and beta-blocker up-to maximal dosages; RAS-antagonist and beta-blocker none or at stable dose
    PhasePhase 4
    Registry statusRecruiting

  • Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy

    NCT00295542 · start 2000-03

    Registered record
    Registry ID
    NCT00295542
    Conditions
    Hypertension
    Interventions
    Ambulatory blood pressure monitoring; Chronotherapy, timing of antihypertensive medication; ACEI (including spirapril, enalapril, quinapril, lisinopril); ARB (including valsartan, telmisartan, olmesartan); beta blockers (including nebivolol, atenolol, carvedilol); diuretics (torasemide, indapamide, HTCZ) and doxazosin; Combination therapy in essential hypertension
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2000-03
    Completion
    2009-04
    Enrolment
    3,344

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAmbulatory blood pressure monitoring; Chronotherapy, timing of antihypertensive medication; ACEI (including spirapril, enalapril, quinapril, lisinopril); ARB (including valsartan, telmisartan, olmesartan) +3 more
    PhasePhase 4
    Registry statusCompleted